LRMR Larimar Therapeutics
- 7.890
- +0.620+8.53%
- 7.860
- -0.030-0.38%
Larimar Therapeutics News
Express News | Larimar Therapeutics Shares Are Trading Higher After the Company Announced That the FDA Removed the Partial Clinical Hold Previously Placed on the Nomlabofusp Clinical Program
Larimar Therapeutics' Friedreich's Ataxia Investigational Drug Differentiated From Biogen's Marketed Drug
On Monday, Larimar Therapeutics Inc (NASDAQ:LRMR) announced that the FDA removed the previous partial clinical hold on -nomlabofusp (CTI-1601) clinical program for Friedreich's Ataxia (FA). Nomlabofus
Why James Hardie Industries Shares Are Trading Lower By Around 14%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Shares of James Hardie Industries plc (NYSE:JHX) fell sharply during Tuesday's session after the company reported worse-than-expected quarterly financial results.James Hardie Industries posted adjuste
Express News | JMP Securities Reiterates Market Outperform on Larimar Therapeutics, Maintains $25 Price Target
Larimar Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/21/2024 194.81% JMP Securities → $25 Reiterates Market Outperform → Market Outperform 04/03/2024 194.81
Buy Rating Reaffirmed for Larimar Therapeutics Post FDA Clinical Hold Lift and Positive Drug Trial Trajectory
XPeng Posts Strong Results, Joins Larimar Therapeutics, Transcat And Other Big Stocks Moving Higher On Tuesday
U.S. stocks were mostly higher, with the Dow Jones index gaining around 50 points on Tuesday.Shares of XPeng Inc. (NYSE:XPEV) rose sharply during Tuesday's session after the company reported better-th
Sector Update: Health Care Stocks Steady Premarket Tuesday
Health care stocks were steady premarket Tuesday, with the the Health Care Select Sector SPDR Fund (XLV) was down a slight 0.1% and the iShares Biotechnology ETF (IBB) recently unchanged. Larimar Ther
Investors Tread Cautiously as Nvidia Earnings Loom, Driving Muted Premarket Action for US Equity Futures
US equity futures were mostly flat premarket Tuesday as traders turned cautious ahead of quarterly earnings from chipmaker Nvidia (NVDA) due for release later in the week. Dow Jones Industrial Average
Sector Update: Health Care
Health care stocks were steady premarket Tuesday as the Health Care Select Sector SPDR Fund (XLV) and iShares Biotechnology ETF (IBB) were recently unchanged. Larimar Therapeutics (LRMR) was rallying
Why Larimar Therapeutics Shares Are Trading Higher By 18%; Here Are 20 Stocks Moving Premarket
Shares of Larimar Therapeutics, Inc.. (NASDAQ:LRMR) rose sharply in today's pre-market trading after the company announced that the FDA removed the partial clinical hold previously placed on the nomla
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
GainersBiodexa Pharmaceuticals (NASDAQ:BDRX) shares increased by 67.7% to $2.13 during Tuesday's pre-market session. The market value of their outstanding shares is at $9.3 million. Durect (NASDAQ:DRR
Top Premarket Gainers
Biodexa Pharmaceuticals (BDRX) shares soared 77% Tuesday premarket, adding to Monday's gains. Edible Garden AG (EDBL) shares surged 52% following a 9% increase in the previous session. Meta Materials
Larimar Therapeutics Says FDA Lifted Partial Clinical Hold For Nomlabofusp In Friedreich's Ataxia
Update: Larimar Therapeutics Gets Partial Hold Lifted on Study of Nervous System Disorder Treatment; Shares Soar Premarket
(Updates with the stock move in the headline and the second paragraph.) Larimar Therapeutics (LRMR) said late Monday the US Food and Drug Administration lifted a partial clinical hold previously impos
Express News | Larimar Therapeutics Shares Rise 20.6% to $8.77 Premarket as FDA Removes Partial Clinical Hold on Genetic Disease Therapy
FDA Decision Propels Larimar (LRMR) Stock In After-Hours Trading
Larimar Therapeutics, Inc. (NASDAQ: LRMR) saw a 17.19% increase in after-hours trading on Monday, reaching $8.52, following a positive regulatory update. Investor excitement over recent advancements in the company's clinical trials is reflected in this notable boost. FDA Lifts Partial Hold On Nomlabofusp Program Larimar Therapeutics (LRMR) announced that the U.S. Food and Drug Administration ...
Larimar Therapeutics (LRMR.US) rose nearly 23% after the market! FDA removes some clinical restrictions on its FA therapy Nomlabofusp
According to some sources, the FDA removed some clinical restrictions on the drug after conducting a phase II data review of the Nomlabofusp clinical project under the new drug developer Larimar Therapeutics.
Larimar Therapeutics Gets Partial Hold Lifted on Study of Nervous System Disorder Treatment
Larimar Therapeutics (LRMR) said Monday the US Food and Drug Administration lifted a partial clinical hold previously imposed on the clinical program to study nomlabofusp for treating Friedreich's Ata
12 Health Care Stocks Moving In Monday's After-Market Session
GainersLarimar Therapeutics (NASDAQ:LRMR) stock increased by 23.6% to $8.99 during Monday's after-market session. The company's market cap stands at $573.5 million. GT Biopharma (NASDAQ:GTBP) stock ro
Analysis
Price Target
No Data
